Objectives: To evaluate the efficacy of alteration from gonadotropin-releasing hormone (GnRH) agonist to antagonist in patients with castration-resistant prostate cancer (CRPC). Methods: Fourteen patients with CRPC were switched from GnRH agonist to GnRH antagonist. CRPC was defined as 3 consecutive rises of PSA values under androgen deprivation therapy despite a testosterone level at the castration level. No patient underwent a change in oral anti-androgen agent or any additional therapy. Patients who showed increase of the PSA value within 10% or showed decrease in the PSA value compared to the baseline were defined as responders. We measured serum PSA, testosterone, follicular stimulating hormone (FSH), and leutenizing hormone (LH) at the time of alteration and 3 months after alteration. Results: The mean age at diagnosis was 74.8 ± 6.3 years with a mean initial PSA level of 537.3 ± 999.1 ng/mL. The mean age at alteration to GnRH antagonist was 81.4 years with a mean PSA level of 28.6 ng/mL. Two out of 14 patients (14%) were judged as responders based on PSA after alteration to GnRH antagonist, although they did not show any further reduction of the serum testosterone level (remain less than 0.03). Six patients showed further reduction of the serum FSH level after alteration; however, they showed no PSA response (from 46.4 ± 42.6 to 69.4 ± 70.3). Conclusions: The switch from GnRH agonist to GnRH antagonist affected 14% of the patients (2 out of 14 patients) with CRPC at 3 months based on PSA. Larger and longer-term studies are required to determine the efficacy of alteration to GnRH antagonist in patients with CRPC.
KeywordsCRPCGnRH AntagonistPSAFSH
Hinotsu, S., Akaza, H., Usami, M., Ogawa, O., Kagawa, S., Kitamura, T., Tsukamoto, T., Naito, S., Namiki, M., Hirao, Y., Murai, M. and Yamanaka, H. (2007) Current Status of Endocrine Therapy for Prostate Cancer in Japan Analysis of Primary Androgen Deprivation Therapy on the Basis of Data Collected by J-CaP. Japanese Journal of Clinical Oncology, 37, 775-781. https://doi.org/10.1093/jjco/hym098
de Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K.N., Jones, R.J., Goodman, O.B. Jr., Saad, F., Staffurth, J.N., Mainwaring, P., Harland, S., Flaig, T.W., Hutson, T.E., Cheng, T., Patterson, H., Hainsworth, J.D., Ryan, C.J., Sternberg, C.N., Ellard, S.L., Fléchon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C.M. and Scher, H.I. (2011) Abiraterone and Increased Survival in Metastatic Prostate Cancer. The New England Journal of Medicine, 364, 1995-2005. https://doi.org/10.1056/NEJMoa1014618
Ryan, C.J., Smith, M.R., de Bono, J.S., Molina, A., Logothetis, C.J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J.M., Ng, S., Carles, J., Mulders, P.F., Basch, E., Small, E.J., Saad, F., Schrijvers, D., Van Poppel, H., Mukherjee, S.D., Suttmann, H., Gerritsen, W.R., Flaig, T.W., George, D.J., Yu, E.Y., Efstathiou, E., Pantuck, A., Winquist, E., Higano, C.S., Taplin, M.E., Park, Y., Kheoh, T., Griffin, T., Scher, H.I. and Rathkopf, D.E. (2013) Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. The New England Journal of Medicine, 368, 138-148. https://doi.org/10.1056/NEJMoa1209096
Scher, H.I., Fizazi, K., Saad, F., Taplin, M.E., Sternberg, C.N., Miller, K., de Wit, R., Mulders, P., Chi, K.N., Shore, N.D., Armstrong, A.J., Flaig, T.W., Fléchon, A., Mainwaring, P., Fleming, M., Hainsworth, J.D., Hirmand, M., Selby, B., Seely, L. and de Bono, J.S. (2012) Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. The New England Journal of Medicine, 367, 1187-1197. https://doi.org/10.1056/NEJMoa1207506
Beer, T.M., Armstrong, A.J., Rathkopf, D.E., Loriot, Y., Sternberg, C.N., Higano, C.S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., Davis, I.D., de Bono, J.S., Evans, C.P., Fizazi, K., Joshua, A.M., Kim, C.S., Kimura, G., Mainwaring, P., Mansbach, H., Miller, K., Noonberg, S.B., Perabo, F., Phung, D., Saad, F., Scher, H.I., Taplin, M.E., Venner, P.M. and Tombal, B. (2014) Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. The New England Journal of Medicine, 371, 424-433. https://doi.org/10.1056/NEJMoa1405095
Tannock, I.F., de Wit, R., Berry, W.R., Horti, J., Pluzanska, A., Chi, K.N., Oudard, S., Théodore, C., James, N.D., Turesson, I., Rosenthal, M.A. and Eisenberger, M.A. (2004) Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. The New England Journal of Medicine, 351, 1502-1512. https://doi.org/10.1056/NEJMoa040720
de Bono, J.S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M.J., Shen, L., Roessner, M., Gupta, S. and Sartor, A.O. (2010) Prednisone plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel Treatment: A Randomised Open-Label Trial. The Lancet, 376, 1147-1154. https://doi.org/10.1016/S0140-6736(10)61389-X
Klotz, L., Boccon-Gibod, L., Shore, N.D., Andreou, C., Persson, B.E., Cantor, P., Jensen, J.K., Olesen, T. K. and Schr?der, F.H. (2008) The Efficacy and Safety of Degarelix: A 12-Month, Comparative, Randomized, Open-Label, Parallel-Group Phase III Study in Patients with Prostate Cancer. BJU International, 102, 1531-1538. https://doi.org/10.1111/j.1464-410X.2008.08183.x
Tombal, B., Miller, K., Boccon-Gibod, L., Schr?der, F., Shore, N., Crawford, E.D., Moul, J., Jensen, J.K., Kold Olesen, T. and Persson, B.E. (2010) Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80 mg versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics. European Urology, 57, 836-842. https://doi.org/10.1016/j.eururo.2009.11.029
Alexandra, M.L., Guy, L., Pedron, P., Bruyere, F., Rouprêt, M., Nsabimbona, B., Dahan, M., Hoffman, P., Salomon, L., Vordos, D., Hoznek, A., Le Corvoisier, P., Morel, P., Abbou, C. and de la Taille, A. (2013) A Switch from GnRH Agonist to GnRH Antagonist in Castration-Resistant Prostate Cancer Patients Leads to a Low Response Rate on PSA. World Journal of Urology, 31, 339-343. https://doi.org/10.1007/s00345-012-0841-1
de la Rosette, J., Davis 3rd, R., Frankel, D. and Kold Olsen, T. (2011) Efficacy and Safety of Androgen Deprivation Therapy after Switching from Monthly Leuprolide to Monthly Degarelix in Patients with Prostate Cancer. International Journal of Clinical Practice, 65, 559-566. https://doi.org/10.1111/j.1742-1241.2011.02637.x
Crawford, E.D., Tombal, B., Miller, K., Boccon-Gibod, L., Schr?der, F., Shore, N., Moul, J.W., Jensen, J.K., Olesen, T.K. and Persson, B.E. (2011) A Phase III Extension Trial with a 1-Arm Crossover from Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer. The Journal of Urology, 186, 889-897. https://doi.org/10.1016/j.juro.2011.04.083
Radu, A., Pichon, C., Camparo, P., Antoine, M., Allory, Y., Couvelard, A., Fromont, G., Hai, M.T. and Ghinea, N. (2010) Expression of Follicle-Stimulating Hormone Receptor in Tumor Blood Vessels. The New England Journal of Medicine, 363, 1621-1630. https://doi.org/10.1056/NEJMoa1001283
Porter, A.T., F.A.C.R.O. and Ben-Josef, E. (2001) Humoral Mechanisms in Prostate Cancer: A Role for FSH. Urologic Oncology, 6, 131-138. https://doi.org/10.1016/S1078-1439(00)00124-1
Miller, K., Russel, C., Goble, S. and Persson, B.E. (2010) Open Label, Exploratory Study of Degarelix as Second-Line Hormonal Therapy in Patients with Prostate Cancer (CS27). European Urology Supplements, 9, 76. https://doi.org/10.1016/S1569-9056(10)60144-3
Morote, J., Orsola, A., Planas, J., Trilla, E., Raventós, C.X., Cecchini, L. and Catalán R. (2007) Redefining Clinically Significant Castration Levels in Patients with Prostate Cancer Receiving Continuous Androgen Deprivation Therapy. The Journal of Urology, 178, 1290-1295. https://doi.org/10.1016/j.juro.2007.05.129
Rove, K.O., Debruyne, F.M., Djavan, B., Gomella, L.G., Koul, H.K., Lucia, M.S., Petrylak, D.P., Shore, N.D., Stone, N.N. and Crawford, E.D. (2012) Role of Testosterone in Managing Advanced Prostate Cancer. Urology, 80, 754-762. https://doi.org/10.1016/j.urology.2012.05.006
Fitzpatrick, J.M., Bellmunt, J., Fizazi, K., Heidenreich, A., Sternberg, C.N., Tombal, B., Alcaraz, A., Bahl, A., Bracarda, S., Di Lorenzo, G., Efstathiou, E., Finn, S.P., Foss?, S., Gillessen, S., Kellokumpu-Lehtinen, P.L., Lecouvet, F.E., Oudard, S., de Reijke, T.M., Robson, C.N., De Santis, M., Seruga, B. and de Wit, R. (2014) Optimal Management of Metastatic Castration-Resistant Prostate Cancer: Highlights from a European Expert Consensus Panel. European Journal of Cancer, 50, 1617-1627. https://doi.org/10.1016/j.ejca.2014.03.010